ABSTRACT
Observations:
Imatinib mesylate, a tyrosine kinase inhibitor, is increasingly being used in the treatment of chronic myeloid leukemia and other oncological disorders. It may cause a large number of cutaneous adverse effects. We are reporting here a case of diffuse universal hyperpigmentation following imatinib therapy, showing lichenoid interface dermatitis on histopathology, a hitherto unreported entity.
